Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts

Journal of Cellular Biochemistry

Volumn 88, Issue 4, 2003, Pages 650-659

  Rifas, Leonard ^a   Arackal, Sophia ^a   Weitzmann, M Neale ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Bone marrow stromal cells; Osteoblasts; Osteoclasts; Runx2; T cells

Indexed keywords

ALKALINE PHOSPHATASE; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; BONE TURNOVER; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ALKALINE PHOSPHATASE; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CULTURE MEDIA, CONDITIONED; CYTOKINES; GLYCOPROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOCALCIN; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; STROMAL CELLS; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0037371342     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10436     Document Type: Article

References (37)

1. Alexander EH, Bento JL, Hughes FM, Jr., Marriott I, Hudson MC, Bost KL. 2001. Staphylococcus aureus and Salmonella enterica serovar Dublin induce tumor necrosis factor-related apoptosis-inducing ligand expression by normal mouse and human osteoblasts. Infect Immun 69:1581-1586.
2. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM. 2000. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640-649.
3. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. 1994. Differentiation of human bone marrow osteogenic stromal cells in vitro: Induction of the osteoblast phenotype by dexamethasone. Endocrinology 134:277-286.
4. Christiansen M, Kveiborg M, Kassem M, Clark BF, Rattan SI. 2000. CBFA1 and topoisomerase I mRNA levels decline during cellular aging of human trabecular osteoblasts. J Gerontol A Biol Sci Med Sci 55:B194-B200.
5. Deodhar AA, Woolf AD. 1996. Bone mass measurement and bone metabolism in rheumatoid arthritis: A review. Br J Rheumatol 35:309-322.
6. Dequeker J, Maenaut K, Verwilghen J, Westhovens R. 1995. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13 (Suppl 12):S21-S26.
7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER; Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
9. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. 2002. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99:491-504.
10. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. 1994. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53: 14-17.
11. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P. 1998. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25: 1282-1289.
12. Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ. 1997. Increased alkaline phosphatase isoforms in autoimmune diseases. Clin Chem 43: 1357-1364.
13. Hay E, Lemonnier J, Modrowski D, Lomri A, Lasmoles F, Marie PJ. 2000. N- and E-cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein-2. J Cell Physiol 183:117-128.
14. Hicok KC, Thomas T, Gori F, Rickard DJ, Spelsberg TC, Riggs BL. 1998. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma. J Bone Miner Res 13: 205-217.
15. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1998. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776-781.
16. Kinne RW, Palombo-Kinne E, Emmrich F. 1997. T-cells in the pathogenesis of rheumatoid arthritis. Villains or accomplices? Biochim Biophys Acta 1360:109-141.
17. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309.
18. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
19. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
20. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. 2001. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18-24.
21. Rickard DJ, Kassem M, Hefferan TE, Sarkar G, Spelsberg TC, Riggs BL. 1996. Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res 11:312-324.
22. Rifas L, Avioli LV. 1999. A novel T cell cytokine stimulates interleukin-6 in human osteoblastic cells. J Bone Miner Res 14:1096-1103.
23. Rifas L, Halstead LR, Peck WA, Avioli LV, Welgus HG. 1989. Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products. J Clin Invest 84: 686-694.
24. Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus HG. 1994. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: Differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology 134:213-221.
25. Rifas L, Kenney JS, Marcelli M, Pacifici R, Cheng SL, Dawson LL, Avioli LV. 1995. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: Evidence that induction by interleukin-1 and tumor necrosis factor-alpha is not regulated by ovarian steroids. Endocrinology 136:4056-4067.
26. Stein GS, Lian JB. 1993. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424-442.
27. Stein GS, Lian JB, Owen TA. 1990. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 4:3111-3123.
28. Suzuki M, Takahashi M, Miyamoto S, Hoshino H, Kushida K, Miura M, Inoue T. 1998. The effects of menopausal status and disease activity on biochemical markers of bone metabolism in female patients with rheumatoid arthritis. Br J Rheumatol 37:653-658.
29. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. 1999. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-4458.
30. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 2002. 8-isoprostaglandin E2 enhances RANKL-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 277:14221-14226.
31. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. 1997. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397.
32. Waters KM, Rickard DJ, Riggs BL, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, Moore J, Spelsberg TC. 2001. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. J Cell Biochem 83:448-462.
33. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R. 2001. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 16:328-337.
34. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
35. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194.
36. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. 1998a. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) - A mechanism by which opg/ocif inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
37. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998b. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.